BridgeBio Pharma Inc
NASDAQ:BBIO 3:58:50 PM EDT
| Market Cap (Intraday) | 4.66B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $27.32 |
| 50-Day MA | $31.04 |
| 200-Day MA | $30.53 |
BridgeBio Pharma Inc Stock, NASDAQ:BBIO
3160 Porter Drive, Suite 250, Palo Alto, California 94304
United States of America
Phone: +1.650.391.9740
Number of Employees: 550
Description
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.